The University of Chicago Header Logo

Connection

Harvey M. Golomb to Combined Modality Therapy

This is a "connection" page, showing publications Harvey M. Golomb has written about Combined Modality Therapy.
Connection Strength

0.440
  1. Management of early-stage Hodgkin's disease: a continuing evolution. Semin Oncol. 1998 Aug; 25(4):476-82.
    View in: PubMed
    Score: 0.029
  2. Clinical studies of docetaxel (Taxotere) and concomitant chest therapy. Semin Oncol. 1997 Aug; 24(4 Suppl 14):S14-26-S14-29.
    View in: PubMed
    Score: 0.027
  3. Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study. Semin Oncol. 1996 Apr; 23(2 Suppl 5):48-52.
    View in: PubMed
    Score: 0.025
  4. Management of pulmonary metastases. Lancet. 1995 Jul 08; 346(8967):68.
    View in: PubMed
    Score: 0.024
  5. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest. Cancer Chemother Pharmacol. 1995; 35(4):304-12.
    View in: PubMed
    Score: 0.023
  6. Concomitant chemoradiotherapy for non-small cell lung cancer. Lung Cancer. 1994 Mar; 10 Suppl 1:S253-61.
    View in: PubMed
    Score: 0.022
  7. The impact on survival by adjuvant chemotherapy and radiation therapy in stage II non-small-cell lung cancer. Am J Clin Oncol. 1992 Oct; 15(5):405-11.
    View in: PubMed
    Score: 0.020
  8. Role of systemic therapy in advanced non-small-cell lung cancer. Am J Med. 1990 Dec; 89(6):777-86.
    View in: PubMed
    Score: 0.017
  9. 5-Fluorouracil with oral leucovorin and hydroxyurea and concomitant radiotherapy for stage III non-small cell lung cancer. Cancer. 1990 Aug 01; 66(3):437-42.
    View in: PubMed
    Score: 0.017
  10. Hairy cell leukemia. Current management. Hematol Oncol Clin North Am. 1990 Apr; 4(2):489-502.
    View in: PubMed
    Score: 0.016
  11. Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study. Chest. 1989 Jul; 96(1):110-3.
    View in: PubMed
    Score: 0.016
  12. What is the choice of treatment for hairy cell leukemia? J Clin Oncol. 1989 Feb; 7(2):156-8.
    View in: PubMed
    Score: 0.015
  13. High-dose, multiple-alkylator chemotherapy with autologous bone marrow reinfusion in patients with advanced non-small cell lung cancer. Cancer. 1989 Jan 15; 63(2):238-42.
    View in: PubMed
    Score: 0.015
  14. Prophylactic cranial irradiation in adenocarcinoma of the lung. A possible role. Cancer. 1987 Jun 15; 59(12):2016-9.
    View in: PubMed
    Score: 0.014
  15. Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia. Semin Oncol. 1987 Jun; 14(2 Suppl 2):13-7.
    View in: PubMed
    Score: 0.014
  16. Guidelines for the treatment of hairy cell leukemia. Leukemia. 1987 Apr; 1(4):405-6.
    View in: PubMed
    Score: 0.013
  17. Hairy cell leukemia and mucormycosis. Treatment with alpha-2 interferon. Am J Med. 1986 Dec; 81(6):1065-7.
    View in: PubMed
    Score: 0.013
  18. A 10-year experience with combined modality therapy for stage III small cell lung carcinoma. Cancer. 1986 Nov 15; 58(10):2177-84.
    View in: PubMed
    Score: 0.013
  19. Modified stage I (T1N0M0, T2N0M0), nonsmall cell lung cancer: treatment results, recurrence patterns, and adjuvant immunotherapy. Surgery. 1986 Oct; 100(4):621-8.
    View in: PubMed
    Score: 0.013
  20. The role of interferon in the treatment of hairy cell leukemia. Semin Oncol. 1986 Sep; 13(3 Suppl 2):21-8.
    View in: PubMed
    Score: 0.013
  21. Perspective on staging approaches in the malignant lymphomas. Surg Gynecol Obstet. 1986 Aug; 163(2):193-201.
    View in: PubMed
    Score: 0.013
  22. Treatment of myeloid blastic crisis of chronic myelogenous leukemia. Cancer Treat Rep. 1984 Nov; 68(11):1351-5.
    View in: PubMed
    Score: 0.011
  23. Hairy cell leukemia: the importance of accurate diagnosis and sequential management. Adv Intern Med. 1984; 29:245-69.
    View in: PubMed
    Score: 0.011
  24. Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. J Clin Oncol. 1998 Jun; 16(6):2157-63.
    View in: PubMed
    Score: 0.007
  25. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol. 1998 Jan; 16(1):159-64.
    View in: PubMed
    Score: 0.007
  26. Ifosfamide plus paclitaxel in advanced non-small-cell lung cancer: a phase I study. Ann Oncol. 1996 Mar; 7(3):314-6.
    View in: PubMed
    Score: 0.006
  27. Radiation therapy for pathologic stage III Hodgkin's disease with and without chemotherapy. Int J Radiat Oncol Biol Phys. 1989 Oct; 17(4):761-6.
    View in: PubMed
    Score: 0.004
  28. Adenosquamous lung carcinoma: clinical characteristics, treatment, and prognosis. Ann Thorac Surg. 1987 Nov; 44(5):462-6.
    View in: PubMed
    Score: 0.003
  29. Durability of responses to interferon alfa-2b in advanced hairy cell leukemia. Blood. 1987 Mar; 69(3):872-7.
    View in: PubMed
    Score: 0.003
  30. Pleural involvement in stage IIIM0 non-small-cell bronchogenic carcinoma. A need to differentiate subtypes. Am J Clin Oncol. 1986 Jun; 9(3):255-61.
    View in: PubMed
    Score: 0.003
  31. The role of adjuvant therapy after resection of T1 N1 M0 and T2 N1 M0 non-small cell lung cancer. J Thorac Cardiovasc Surg. 1986 Mar; 91(3):344-9.
    View in: PubMed
    Score: 0.003
  32. Long-term survival of patients with localized diffuse histiocytic lymphoma. J Clin Oncol. 1985 Oct; 3(10):1309-17.
    View in: PubMed
    Score: 0.003
  33. Combined modality therapy for Stage IIIMO non-small cell lung cancer. A five-year experience. Cancer. 1984 Jul 01; 54(1):5-12.
    View in: PubMed
    Score: 0.003
  34. The use of serum albumin for further classification of Stage III non-oat cell lung cancer and its therapeutic implications. Ann Thorac Surg. 1984 Feb; 37(2):115-22.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.